In vivo efficacy and toxicity of intratumorally delivered mitomycin C and its combination with doxorubicin using microsphere formulations

被引:29
作者
Cheung, RY
Rauth, AW
Wu, XY
机构
[1] Univ Toronto, Leslie Dean Fac Pharm, Toronto, ON M5S 2S2, Canada
[2] Ontario Canc Inst, Toronto, ON M4X 1K9, Canada
关键词
doxorubicin; intratumoral delivery; in vivo efficacy; microsphere; mitomycin C; solid tumors; toxicity;
D O I
10.1097/00001813-200504000-00009
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
The efficacy and toxicity of intratumorally (i.t.) administered anticancer drugs mitomycin C (MMC) and doxorubicin (Dox) incorporated in polymeric microspheres were investigated. Biodegradable sulfopropyl dextran microspheres and their oxidized products were used to load Dox and MMC, respectively. EMT6 mouse mammary cancer cells were injected into the hind leg of BALB/c mice. MMC microspheres, alone or combined with Dox microspheres, were injected i.t. once tumors had reached around 0.3 g. The tumor-plus-leg diameter was measured daily and the delay in time for the tumor to grow to 1.13 g relative to control (TGD) was employed as an indication of therapeutic effect. General toxicity was determined by monitoring weight, appearance and behavior of the mice. Morphology and histology of tumor and heart tissues were also examined. An average 79% TGD was observed after i.t. injection of MMC microspheres. The i.t. co-administration of MMC and Dox microspheres resulted in a 185% TGD. The i.t. injections of the microsphere formulations did not result in visible signs of toxicity in animals. In contrast, systemic (i.e. i.p.) injections of MMC solutions caused considerable general toxicity. This study suggests that i.t. delivery of anticancer drugs by polymeric microspheres is an effective way of improving the therapeutic index for cancer chemotherapy of selected solid tumors under special conditions. (c) 2005 Lippincott Williams & Wilkins.
引用
收藏
页码:423 / 433
页数:11
相关论文
共 47 条
[1]
Efficacy of mitoxantrone-loaded albumin microspheres for intratumoral chemotherapy of breast cancer [J].
Almond, BA ;
Hadba, AR ;
Freeman, ST ;
Cuevas, BJ ;
York, AM ;
Detrisac, CJ ;
Goldberg, EP .
JOURNAL OF CONTROLLED RELEASE, 2003, 91 (1-2) :147-155
[2]
P-glycoprotein: from genomics to mechanism [J].
Ambudkar, SV ;
Kimchi-Sarfaty, C ;
Sauna, ZE ;
Gottesman, MM .
ONCOGENE, 2003, 22 (47) :7468-7485
[3]
ANDERSON JH, 1994, MICROSPHERES REGIONA, P57
[4]
ANDERSSON M, 1986, CANCER TREAT REP, V70, P1181
[5]
BERTAZZOLI C, 1979, CANCER TREAT REP, V63, P1877
[6]
BOYER MJ, 1998, BASIC SCI ONCOLOGY, P350
[7]
GROWTH AND CHEMOTHERAPEUTIC RESPONSE OF CELLS IN A HOLLOW-FIBER IN-VITRO SOLID TUMOR-MODEL [J].
CASCIARI, JJ ;
HOLLINGSHEAD, MG ;
ALLEY, MC ;
MAYO, JG ;
MALSPEIS, L ;
MIYAUCHI, S ;
GREVER, MR ;
WEINSTEIN, JN .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (24) :1846-1852
[8]
A new approach to the in vivo and in vitro investigation of drug release from locoregionally delivered microspheres [J].
Cheung, RY ;
Kuba, R ;
Rauth, AM ;
Wu, XY .
JOURNAL OF CONTROLLED RELEASE, 2004, 100 (01) :121-133
[9]
CHEUNG RY, 2005, IN PRESS BIOMATERIAL
[10]
CHEUNG RY, UNPUB MICROSPHERE DE